• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Thalidomide may be effective in refractory pediatric Crohn’s disease

bys25qthea
November 27, 2013
in Chronic Disease, Gastroenterology, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/Wiki

1. After 8 weeks of treatment, thalidomide demonstrated improved rates of clinical remission as compared to placebo.

2. The mean duration of the remission induced by thalidomide was 181 weeks versus the 6 weeks noted in the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: About a quarter of adult Crohn’s disease patients report symptoms during childhood. Such pediatric-onset of the disease is marked by both a high severity of symptoms and recalcitrance to treatment options. While observational studies on the use of thalidomide, an anti-TNF alpha agent, in Crohn’s disease have reported encouraging results, the present study represents the first randomized controlled trial assessing its efficacy in inducing clinical remission in the pediatric population. The promising findings of this study with regards to remission induction and maintenance highlight the potential utility of thalidomide use in this population. Although the incidence of adverse effects in this study was felt to be acceptable compared to currently utilized immunosuppressant therapy, the study was underpowered to detect rare adverse effects and a more thorough assessment of the safety profile of thalidomide would be helpful prior to its implementation routine clinical care.

Click to read the study, published today in JAMA

Relevant Reading: Specificities of inflammatory bowel disease in childhood

RELATED REPORTS

Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

In-Depth [randomized controlled trial]: In this double-blind, placebo-controlled, randomized clinical trial, researchers assembled a cohort of 56 children with active Crohn’s disease refractory to immunosuppression across six pediatric tertiary control centers. Twenty-eight of these children were randomized to receive daily thalidomide while 26 were given daily placebo pills. The Pediatric Crohn Disease Activity Index (PCDAI) was utilized to measure the disease activity at enrollment and track its progression throughout the trial. Clinical remission was assessed at week 8 by a PCDAI score of 10 or less and this was seen in 46.4% of thalidomide recipients versus 11.5% in controls (95%CI, 1.2-12.5). Mean duration of remission was 181.1 weeks (95%CI, 1.4-217.76) in the experimental group and 6.3 weeks (95%CI, 3.51-9.15) in placebo. Of note, peripheral neuropathy was noted to be the most frequent severe adverse event with an incidence noted of 2.1 per 1000 patient-weeks (95%CI, 1.1-4.1).

By Priyanka Vedak and Rif Rahman

More from this author: High cumulative-dose isotretinoin treatment decreases risk of acne relapse, Conjugated equine estrogens may elevate risk of venous thrombosis, Iron use does not increase incidence of malaria in young children, Childhood food allergies associated with significant direct medical costs, Universal glove use not associated with reduction in acquiring antibiotic-resistance bacteria

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: Crohn's DiseaseIBDthalidomide
Previous Post

Lower household income associated with higher pediatric inpatient costs

Next Post

Hypercortisolism of bilateral macronodular adrenal hyperplasia may be corticotropin-dependent

RelatedReports

Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes

October 10, 2022
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

September 14, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

August 11, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
Next Post
Hypercortisolism of bilateral macronodular adrenal hyperplasia may be corticotropin-dependent

Hypercortisolism of bilateral macronodular adrenal hyperplasia may be corticotropin-dependent

New pathogenic dimorphic fungal species suggested in HIV-positive patients

Micronutrient supplementation linked with decreased HIV-disease progression

The RIVAL trial: Radial vs femoral artery access for PCI [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
  • Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options